• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Chow Carlton

    6/10/25 5:33:41 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care
    Get the next $SRTS alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Chow Carlton

    (Last) (First) (Middle)
    851 BROKEN SOUND PARKWAY NW #215

    (Street)
    BOCA RATON FL 33487

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    05/19/2025
    3. Issuer Name and Ticker or Trading Symbol
    Sensus Healthcare, Inc. [ SRTS ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Technology Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Carlton Chow 06/09/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SRTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRTS

    DatePrice TargetRatingAnalyst
    1/31/2025$18.00Buy
    Lake Street
    11/15/2024$12.00 → $14.00Buy
    Maxim Group
    3/3/2022$12.00 → $13.00Buy
    HC Wainwright & Co.
    2/14/2022$10.00 → $12.00Buy
    HC Wainwright & Co.
    12/2/2021$9.00 → $10.00Buy
    HC Wainwright & Co.
    11/5/2021$7.00 → $9.00Buy
    HC Wainwright & Co.
    8/6/2021$6.00 → $7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SRTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Sensus Healthcare with a new price target

    Lake Street initiated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $18.00

    1/31/25 9:07:11 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Maxim Group reiterated coverage on Sensus Healthcare with a new price target

    Maxim Group reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $14.00 from $12.00 previously

    11/15/24 8:09:06 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Sensus Healthcare with a new price target

    HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $13.00 from $12.00 previously

    3/3/22 6:32:52 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sensus Healthcare Expands Role of President Michael Sardano to Include Chief Commercial Officer

    New responsibilities recognize Mr. Sardano's significant accomplishments in securing CPT® codes for office-based SRT and the growing commercial opportunity the Company now faces Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that President Michael Sardano has been appointed to the additional role of Chief Commercial Officer. In this newly created position, Mr. Sardano will direct the company's global sales, marketing and commercial strategy across its portfolio of SRT technologies, Sentinel® software and rela

    11/14/25 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Appoints Eric Sachetta to its Board of Directors

    Seasoned financial executive brings leadership acumen, strategic growth expertise and a strong track record of operational excellence Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company's Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the passing of long-serving Director Bill McCall. Throughout his career, Mr. Sachetta has held a range of leadership roles focused on organizational growth, team development, sales performance and operation

    11/12/25 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Reports Third Quarter 2025 Financial Results

    Centers for Medicare & Medicaid Services (CMS) established coding validating superficial radiotherapy (SRT) for treating non-melanoma skin cancer Revenues of $6.9 million Shipped 16 SRT systems including three to China Fair Deal Agreement (FDA) treatment volume increased 20% over the second quarter Exited the quarter with $24.5 million in cash and no debt Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months end

    11/6/25 4:05:00 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    SEC Filings

    View All

    $SRTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sensus Healthcare Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Sensus Healthcare, Inc. (0001494891) (Filer)

    11/13/25 10:06:55 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Sensus Healthcare Inc.

    10-Q - Sensus Healthcare, Inc. (0001494891) (Filer)

    11/12/25 2:56:42 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Sensus Healthcare, Inc. (0001494891) (Filer)

    11/6/25 4:15:45 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Director Sachetta Eric bought $27,510 worth of shares (7,000 units at $3.93), increasing direct ownership by 5% to 140,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/21/25 2:28:31 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Director Sachetta Eric bought $11,250 worth of shares (2,500 units at $4.50), increasing direct ownership by 2% to 133,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/20/25 2:03:11 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    CHIEF EXECUTIVE OFFICER Sardano Joseph C bought $100,750 worth of shares (25,000 units at $4.03), increasing direct ownership by 2% to 1,200,293 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/19/25 9:34:10 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sachetta Eric bought $27,510 worth of shares (7,000 units at $3.93), increasing direct ownership by 5% to 140,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/21/25 2:28:31 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Director Sachetta Eric bought $11,250 worth of shares (2,500 units at $4.50), increasing direct ownership by 2% to 133,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/20/25 2:03:11 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    New insider Sachetta Eric claimed ownership of 132,706 shares (SEC Form 3)

    3 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/20/25 1:55:42 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Leadership Updates

    Live Leadership Updates

    View All

    Sensus Healthcare Appoints Eric Sachetta to its Board of Directors

    Seasoned financial executive brings leadership acumen, strategic growth expertise and a strong track record of operational excellence Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company's Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the passing of long-serving Director Bill McCall. Throughout his career, Mr. Sachetta has held a range of leadership roles focused on organizational growth, team development, sales performance and operation

    11/12/25 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Celebrates Skin Cancer Awareness Month by Promoting Awareness and Spotlighting its Patient-Friendly, Non-Invasive Treatments

    Innovative SRT-100 Vision (IG-SRT) and SRT Vision Technologies allow dermatologists to treat non-melanoma skin cancer without surgery or patient downtime May is Skin Cancer Awareness Month and Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, is leveraging a wide range of activities to draw attention to the importance of prevention, early detection and treatment of the most common form of cancer that affects millions of people worldwide. Throughout the month of May, Sensus Healthcare is actively promoting skin cancer awareness

    5/1/25 4:30:00 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Announces Retirement of Director Samuel O'Rear

    BOCA RATON, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Samuel O'Rear will not stand for reelection to the Company's Board of Directors at the Company's 2024 annual meeting of stockholders.  Mr. O'Rear has been a Director of Sensus Healthcare since 2012. As previously announced, on January 11, 2024 the Board of Directors of Sensus Healthcare appointed Michael J. Sardano, President and General Counsel of Sensus Healthcare, as a Director, effective today. "Sam has been inv

    2/1/24 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

    SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

    2/6/24 12:27:47 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

    SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

    2/10/23 11:51:22 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

    SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

    2/7/22 8:30:08 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Financials

    Live finance-specific insights

    View All

    Sensus Healthcare Reports Third Quarter 2025 Financial Results

    Centers for Medicare & Medicaid Services (CMS) established coding validating superficial radiotherapy (SRT) for treating non-melanoma skin cancer Revenues of $6.9 million Shipped 16 SRT systems including three to China Fair Deal Agreement (FDA) treatment volume increased 20% over the second quarter Exited the quarter with $24.5 million in cash and no debt Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months end

    11/6/25 4:05:00 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare to Report Third Quarter 2025 Financial Results and Hold Business Update Conference Call on November 6

    Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the third quarter of 2025 on Thursday, November 6, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the cal

    10/23/25 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Reports Second Quarter 2025 Financial Results

    Shipped 19 SRT systems during the quarter, including four to China Revenues of $7.3 million FDA treatment volume increased 27% over the first quarter Exited the quarter with $22.2 million in cash and no debt Proposed Physician Fee Schedule expected to favorably impact adoption of SRT technology beginning in 2026 Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and six months ended June 30, 2025. Highlights of the

    8/7/25 4:05:00 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care